FORM PTO-1449 (Modified)			Attorney Docket No.:		Application No.					
LIST OF PATENTS AND PUBLICATIONS FOR			Applicant: Min Michael He et al:							
APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)			Filing Date:		Group:					
Reference Designation U.S. PATENT DOCUMENTS Page 1										
Examiner Initial	Document No.	Date	Name	Class	Sub-class	Filing Date (If Appropriate)				
AA										
AB										
AC										
AD										
AE										
AF										
AG										
АН										
AI					<u>-</u>					
AJ		-								
AK										
AL			•			·				
	·									
FOREIGN PATENT DOCUMENTS										
	Document No.	Date	Country	Class	Sub-class	Translation (Yes/No)				
<u> KG</u> am	DE 197 32 855 A1	0218/99	Indena	A61K	35/78	No				
_KC an	DE 197 32 866 A1	02/18/99	Indena	A61K	3578	No				
AO	-									
AP										
AQ										
AR				,						
				·						
	го	HER ART (Inclu	iding Author, Title, Date, P	ertinent Pages, E	tc.)					
<u> LG</u> AS	Derwent Publication Ltd., Lodon, GB, Class A96, AN 1997-534403 XP002151122									
AT										
AU				*******						
AV										
AW				·						
	EXAMINER KA-M.C. — DATE CONSIDERED 6.7.04									
EXAMINER	Karton III	/	DATE CONSIDERED	6.7.04		1				

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

٠, ٤

FORM PTO-1449 (Modified)			Attorney Docket No.:		Application No.:					
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE			Applicant: Min Michael He, Fang-yu Liu, Joseph A. Fix, Martin Link, Maria L. Kang and Ezio Bombardelli							
STATEMENT (Use several sheets if necessary)			Filing Date: Group:							
Reference Desig	nation	τ	J.S. PATENT DOCUMENTS Page 1							
Examiner Initial	Document No.	Date	Name	Class	Sub-class	Filing Date (If Appropriate)				
KG AA	5,830,887	11/03/98	Kelly	514	182					
AB	5,674,548	10/07/97	Nakamura et.al.	426	598					
AC	5,855,892	01/05/99	Potter et. al.	424	195.1					
<u>K6</u> AD	5,858,449	01/12/99	Crank et. al.	426	656					
AE										
FOREIGN PATENT DOCUMENTS										
	Document No.	Date	Country	Class	Sub-class	Translation (Yes/No)				
AF										
AG										
	07	THER ART (Inclu	uding Author, Title, Date, P	ertinent Pages, E	ite.)					
<u>K6</u> AH	Anthony, et. al.: "Effects of soy insoflavones on atherosclerosis: potential mechanisms ¹⁻³ " Am J Clin Nutr 1998; (68) (suppl): 1390S-3S									
AI	Greg Peterson and Stephen Barnes: "Genistein inhibition of the growth of human breast cancer cells: Independence from estrogen receptors and the multi-drug resistence gene" Biochemical and Biophysical Research Communications 08/30/91 Vol. 179, No. 1, pages (661-667)									
AJ	Lee-Jane W Lu and Karl E. Anderson: "Sex and long-term soy diets affect the metabolism and excretion of soy isolflavones in humans 1-3" Am J Clin Nutr 1998; (68) (suppl): 1500S-4S									
AK	Zhang, et. al.: "Daidzein and Genistein Glucuronides in Vitro are weakly estrogenic and activate human natural killer cells at nutritionally relevant concentrations 1.2.3" J. Nutr. 129: 399-405 (1999)									
AL	Mark Messina and Stephen Barnes: "The Role of Soy Products in Reducing Risk of Cancer 1" Journal of the National Cancer Institute Vol. 83, No. 8, 541-546 (4/17/91)									
AM	Greg Peterson and Stephen Barnes: "Genistein and Biochanin A Inhibit the Growth of Human Prostate Cancer Cells but not Epidermal Growth Factor Receptor Tyrosine Autophosphorylation" The Prostate 22: 335-345 (1993)									
AN	Charland et. al.: "The effects of a soybean extract on tumor growth and metastasis" International Journal of Molecular Medicine 2: 225-228 (1998)									
K6A0	Kathleen A. Head, N.D. "Ipriflavone: An Important Bone-Building Isoflavone" Alternative Medicine Review Vol. 4, No. 1, 10-22 (1999)									
AP	., 1, 10-22		•							
AQ										
FYAMINER	V-5-10 (DATE CONSIDERED	6.7.04						

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.